JADENU Drug Patent Profile

When do Jadenu patents expire, and what generic alternatives are available?

Jadenu is a drug marketed by Novartis Pharms Corp and Novartis and is included in two NDAs. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has sixty-eight patent family members in forty-three countries.

The generic ingredient in JADENU is deferasirox. There are twenty drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the deferasirox profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Jadenu

A generic version of JADENU was approved as deferasirox by ACTAVIS ELIZABETH on January 26^th, 2016.

Summary for JADENU

International Patents:	68
US Patents:	1
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2
Patent Applications:	1,698
Drug Prices:	Drug price information for JADENU
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JADENU
What excipients (inactive ingredients) are in JADENU?	JADENU excipients list
DailyMed Link:	JADENU at DailyMed

See drug prices for JADENU

Recent Clinical Trials for JADENU

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
DisperSol Technologies, LLC	Phase 2
Novartis Pharmaceuticals	Phase 2

See all JADENU clinical trials

Pharmacology for JADENU

Drug Class	Iron Chelator
Mechanism of Action	Cytochrome P450 1A2 Inhibitors Cytochrome P450 2C8 Inhibitors Cytochrome P450 3A4 Inducers Iron Chelating Activity

Paragraph IV (Patent) Challenges for JADENU

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JADENU	Tablets	deferasirox	180 mg	206910	1	2016-04-21
JADENU	Tablets	deferasirox	90 mg and 360 mg	206910	1	2015-10-19

US Patents and Regulatory Information for JADENU

JADENU is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-001	Mar 30, 2015	AB	RX	Yes	No	9,283,209		Y	Y
Novartis	JADENU SPRINKLE	deferasirox	GRANULE;ORAL	207968-001	May 18, 2017	AB	RX	Yes	No
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-002	Mar 30, 2015	AB	RX	Yes	No	9,283,209		Y	Y
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-003	Mar 30, 2015	AB	RX	Yes	Yes	9,283,209		Y	Y

Expired US Patents for JADENU

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-003	Mar 30, 2015	6,596,750
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-001	Mar 30, 2015	6,465,504
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-002	Mar 30, 2015	6,465,504
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-003	Mar 30, 2015	6,465,504

EU/EMA Drug Approvals for JADENU

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mylan Pharmaceuticals Limited	Deferasirox Mylan	deferasirox	EMEA/H/C/005014Deferasirox Mylan is indicated forthe treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and olderthe treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years,in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (	Authorised	yes	no	no	2019-09-26
Novartis Europharm Limited	Exjade	deferasirox	EMEA/H/C/000670Exjade is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged six years and older.Exjade is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) aged two to five years;in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (< 7 ml/kg/month of packed red blood cells) aged two years and older;in patients with other anaemias aged two years and older.Exjade is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older.	Authorised	no	no	no	2006-08-28
Accord Healthcare S.L.U.	Deferasirox Accord	deferasirox	EMEA/H/C/005156Deferasirox Accord is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older.Deferasirox Accord is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years,in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (	Authorised	yes	no	no	2020-01-09

International Patents for JADENU

See the table below for patents covering JADENU around the world.

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	1127	Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators.
African Regional IP Organization (ARIPO)	9801407
Argentina	007479	UN COMPUESTO DERIVADO DEL 3,5-DIFENIL-1,2,4-TRIAZOL SUSTITUIDO, SU USO, UN PROCEDIMIENTO PARA PREPARARLO Y UNA PREPARACION FARMACEUTICA QUE LO COMPRENDE.
Austria	226435

Supplementary Protection Certificates for JADENU

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0914118	300248	Netherlands		300248, 20170624, EXPIRES: 20210827
0914118	PA2007001	Lithuania		PRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006 08 28, EU/1/06/356/002 2006 08 28, EU/1/06/356/003 2006 08 28, EU/1/06/356/004 2006 08 28, EU/1/06/356/005 2006 08 28, EU/1/06/356/00 20060828
0914118	CA 2006 00035	Denmark
0914118	06C0049	France		PRODUCT NAME: DEFERASIROX OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/06/356/001 DU 20060828; REGISTRATION NO/DATE AT EEC: EU/1/06/356/001 DU 20060828

Jadenu (deferasirox) Market Dynamics and Financial Trajectory: Revenue Drivers, Competitive Pressure, and Exclusivity/IP Outlook

Last updated: July 24, 2026

Executive summary: Jadenu (deferasirox) remains a commercially established iron chelator for chronic iron overload, supported by long-term patient use and incremental uptake driven by dosing convenience and tolerability management. The product’s financial trajectory is shaped by (1) ongoing demand in transfusion-dependent and non-transfusion-dependent iron overload, (2) substitution risk from competing chelators with entrenched formularies, and (3) U.S. branded/generic mix dynamics tied to deferasirox’s patent and Orange Book landscape. Trade-off risk centers on competitive penetration by older branded agents, pricing pressure from payers, and the pace of generic entry by route and strength where exclusivity has cleared.

---

What is Jadenu and how does it make money? Revenue drivers for deferasirox

Jadenu is a once-daily oral iron chelator containing deferasirox. It targets chronic iron overload in patients who receive blood transfusions (including thalassemia syndromes and other transfusion-dependent anemias) and in patients with non-transfusion-dependent iron overload under specified clinical conditions. Commercial performance typically tracks:

• Patient prevalence and retention: chronic iron chelation creates long treatment duration, supporting baseline revenue even as incident cohorts mature.
• Dose optimization and adherence: deferasirox’s once-daily positioning generally improves adherence vs more frequent regimens, which can expand effective treated populations.
• Formulary and reimbursement execution: payer adoption is sensitive to clinical support documentation, lab monitoring compliance, and evidence of tolerability.

Which indications drive uptake (transfusion-dependent vs non-transfusion-dependent iron overload)?

• Transfusion-dependent iron overload is the largest commercial funnel, reflecting the broader transfusion-dependent population treated with chelation programs.
• Non-transfusion-dependent iron overload is typically a smaller but stabilizing segment where clinicians use deferasirox only when iron metrics and risk thresholds align with label criteria.

How do dosing strength, titration, and monitoring affect revenue?

• Strength mix influences realized pricing and reimbursement outcomes.
• Revenue is also affected by titration velocity (how quickly prescribers move from initiation to target dosing) and by dose interruptions or reductions tied to adverse events and lab changes (renal/hepatic monitoring patterns).

---

How is Jadenu competing in the iron chelator market? What are the key rivals and substitution risks?

Jadenu competes in a mature iron chelation category where prescribers select based on tolerability, dosing convenience, and payer constraints.

Who are Jadenu’s main competitors?

• Exjade/Exjade-like deferasirox products (when available by generic or branded form depending on geography and time period)
• Desferal (deferoxamine) for patients needing parenteral chelation or when oral tolerability fails
• Ferriprox (deferiprone) for specific clinical use cases and prescriber preference patterns

What drives payer behavior in chelators?

• Step therapy and coverage criteria often reflect a preference for cost-effective oral agents where clinically appropriate.
• Payers may require iron burden documentation, adherence verification, and monitoring schedules to minimize off-label use.

Where does Jadenu face the highest substitution risk?

• Where brand-to-brand switching is achievable due to similar clinical endpoints.
• When generic deferasirox options (or multiple-supplier deferasirox equivalents) improve cost competitiveness and reduce payer resistance.

---

When does Jadenu lose exclusivity? Patent expiration and exclusivity timeline for deferasirox products

This section cannot be completed accurately without the specific U.S. branded product’s Orange Book exclusivity and the latest patent listing set for Jadenu (including method-of-use, formulation, and device/container closure patents as listed by FDA). The financial trajectory and generic entry risk must be tied to those listings. Without the Orange Book and the exact Jadenu listing set, a precise exclusivity timeline would be incomplete.

---

What is the Orange Book status of Jadenu? How many patents cover the product?

This section cannot be produced accurately without the current FDA Orange Book listing for Jadenu, including:

• Listed drug product patents (formulation/composition)
• Listed method-of-use patents (indication-specific)
• Listed patents with expiration dates
• Any 30-month stay or 180-day exclusivity indicators tied to Abbreviated New Drug Applications

Without the Orange Book dataset for Jadenu’s exact FDA listing(s), the “how many patents” and “status” elements cannot be stated with required precision.

---

What generic entry risks exist for Jadenu? Paragraph IV and litigation scenarios

A defensible generic entry risk profile requires:

• Whether any ANDAs for Jadenu’s NDA have been filed under Paragraph IV
• The resulting Hatch-Waxman litigation and whether a 30-month stay applied
• Whether any ANDA sponsor secured 180-day exclusivity

Without confirmation from litigation dockets and FDA/Orange Book updates for Jadenu, this section would risk incorrect statements about launch timing and market-share disruption.

---

How do method-of-use and formulation patents affect Jadenu pricing and generic competition?

To analyze patent-driven pricing power, this section must map:

• Which patents protect iron overload indications, dosing regimens, and monitoring-driven methods
• Which patents protect formulation aspects (for example, film coating, tablet composition, granulation approach, dissolution profile)
• Whether those patents are likely to be “work-around” targets for ANDA manufacturers

Without the identified Jadenu patent family and the claims that were listed in the Orange Book, an accurate method/formulation impact analysis is not possible.

---

What patent litigation affects Jadenu? Settlement agreements and launch triggers

A complete financial trajectory view depends on knowing:

• Whether Jadenu was subject to Hatch-Waxman litigation
• Whether settlements included brand-only supply terms, delayed launch commitments, or agreed carve-outs
• Whether any license agreements exist that shape market entry dates and volumes

Without specific litigation and settlement records tied to Jadenu’s NDA and patent listings, this section cannot be completed.

---

What are the FDA regulatory milestones for Jadenu and how do they translate into sales?

A correct milestone-to-revenue linkage requires the NDA/label chronology:

• Initial approval date
• Label expansions (new strengths, pediatric guidance, non-transfusion-dependent iron overload changes)
• Post-marketing safety communications that changed dosing or monitoring requirements

Without the approved labeling timeline for Jadenu in the current market, the regulatory timeline would not map reliably to sales changes.

---

How does Jadenu compare with Exjade and Ferriprox on market performance and adoption?

A quantitative comparison requires reliable market-share and revenue disclosures for:

• Branded and generic deferasirox products under different trade names and suppliers
• Sales for alternative chelators by year in the same geography
• Public payer formularies and claims-based adoption data

Without these datasets, a comparison would be non-actionable for financial trajectory decisions.

---

Commercial trajectory outlook for Jadenu: base case drivers and downside risks

Even without patent-precision for exclusivity dates, the commercial trajectory in chelators generally follows a pattern:

Base case drivers

• Chronic use durability: patients remain on chelation for years, so revenue often declines more slowly than acute-care products.
• Adherence advantage: once-daily oral dosing supports retention, keeping demand more resilient during competitive cycles.
• Clinical switching control: prescribers may stay on a tolerated agent even when alternatives exist, limiting immediate substitution.

Key downside risks

• Pricing pressure: any entry of lower-cost deferasirox equivalents typically compresses net price and may shift patient share.
• Payer edits: formulary tightening can reduce initiation even if ongoing treatment continues.
• Tolerability and monitoring burden: adverse event profiles and lab monitoring requirements can raise real-world discontinuation rates.

What matters most to financial trajectory

• Net-to-gross evolution (rebates and discounts)
• Share stability vs generic pressure by strength and channel
• Retention rates by tolerability subgroups and monitoring adherence

---

Key market dynamics by channel: how Jadenu revenue changes with contracts and reimbursement

Hospital vs specialty pharmacy dynamics

• Chronic chelation often routes through specialty distribution networks.
• Reimbursement policies influence access for initiation, which can be more volatile than continuation.

Payer mix and outcomes-based utilization

• Some payers use utilization management tied to lab thresholds and physician documentation.
• Patients with stable iron metrics are generally less likely to be interrupted, supporting continuity.

---

Key Takeaways

• Jadenu revenue dynamics are dominated by long-duration patient retention, oral adherence, and payer execution in chronic iron overload.
• The biggest financial swing factor is deferasirox competitive pricing as branded-to-generic or multi-supplier competition tightens net price.
• Patent and Orange Book structure determines the timing and likelihood of generic entry, which then drives share and margin compression.
• Commercial durability remains supported by chelation treatment persistence, but initiation and net pricing are exposed to payer contract renegotiations.

---

FAQs

1) What factors most affect Jadenu net price over time?

Net price is most sensitive to payer rebates, formulary placement changes, and strength mix shifts as competition expands.

2) Does Jadenu face more competition in transfusion-dependent or non-transfusion-dependent iron overload?

Commercially, competition pressure is usually heavier where patient volumes are larger and prescribing is more standardized. Transfusion-dependent populations generally drive the larger competitive footprint.

3) How do real-world discontinuation and monitoring burden impact Jadenu sales?

Higher discontinuation rates tied to tolerability or lab abnormalities reduce treated patient prevalence and can lower annual sales growth, even if label retention remains strong.

4) What channel is most important for Jadenu distribution economics?

Specialty pharmacy distribution economics often dominate chronic oral therapies through reimbursement and dispensing cadence.

5) What’s the revenue impact when deferasirox generics expand availability?

Typically the effect is rapid net price compression and patient switching to lower-cost equivalents, while some continuity persists due to tolerated therapy and prescriber inertia.

---

References

No sources were provided in the prompt, and no Orange Book, FDA label timeline, litigation docket, or revenue disclosure set for Jadenu was included; therefore, no citations can be listed without risking incorrect attribution.